Drug Trial Radar · NCT05404529
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 29, 2022
Primary completion
Jan 24, 2023
Study completion Jan 24, 2023
Sponsor
- Lead sponsor
- Cerevel Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
TavapadonDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7
- Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7
- Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Miami, Florida
Miami, Florida
Orlando, Florida
Orlando, Florida
San Antonio, Texas
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.